NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Changes were made to the methods and processes for health technology evaluations in the UK. Evaluations that were started prior to February 1, 2022 will be evaluated using the oder methods. However, new evaluations will benefit from the use of the updated and more flexible process. Perhaps Northwest Bio would prefer to begin a new evaluation so that DCVax-L is evaluated using the updated methods and processes?

NICE Technology appraisal guidance

Content under review
We're updating this page following the publication of our new methods, processes and topic selection manuals. Our previous manuals still apply to evaluations that started before 1 February 2022. The new manuals apply to evaluations that began after this date.

https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance


Changes we're making to health technology evaluation
We've now published our updated manuals for methods, processes and topic selection.
They cover:
* how we choose medicines and other health technologies to evaluate (topic selection)
* the steps and stages in each evaluation (our processes)
* how we collect and consider evidence (our methods).
The new methods and processes are used for all new evaluations starting from 1 February.
* View the guidance development manual.
* View the topic selection manual.

What's changed and why
The changes we've made aim to streamline and improve the way we carry out health technology evaluation. We've now produced a single guidance development manual, covering:
* diagnostic assessment
* highly specialised technologies
* medical technologies evaluation
* technology appraisal.
We've also developed a new topic selection manual.

Changes we've made
We've made a broad range of improvements to how we evaluate health technologies, including:
* We'll give more weight to health benefits in the most severe conditions. We've made this change because evidence shows that people in the UK value access to treatments for the most severe diseases.
* We're adopting a new approach to the evidence we consider in our assessments.
* We’re allowing more flexibility for NICE’s independent committees in cases when generating evidence is difficult.
* We’ve adopted a clearer vision, principles and routing criteria for treatments for very rare diseases in our Highly Specialised Technologies (HST) Programme.
* We're aligning our methods and processes across different types of evaluations. This will ensure that the way we evaluate health technologies is pragmatic, agile and robust, while also being adaptable.

Evidence and considerations
We've carefully reviewed evidence and conducted thorough consultations to inform the changes we've made.
We've previously consulted on:
* methods, processes and topic selection for health technology evaluation: proposals for change
* reviewing our process for health technology evaluation
* topic selection
* the case for change to the methods of health technology evaluation.

https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation